బయోఅనాలిసిస్ & బయోమెడిసిన్ జర్నల్

A Study to Assess the Awareness of the Biosimilars among Ukrainian Physicians

Abstract

Ildar Akhmetov, Raheem Farista and Phani Kishore Thimmaraju

Biologics have revolutionized the treatment for severe chronic illness and rare diseases. They represent the fastest growing segment in the pharmaceutical industry. However due to high of innovator biologics, the alternate options such as biosimilars have emerged. The impending patent cliff, rising healthcare costs and increasing awareness of biosimilars among physicians are crucial factors which will drive biosimilar uptake in future. Europe has demonstrated its faith in biosimilar treatment and EMA has approved several biosimilars since 2006. Over the years, Ukraine has been a favourable market for branded generics and its evolving regulatory landscape for biosimilar approval is an indication of its preparedness to embrace biosimilars. The current survey attempts to assess the awareness of the biosimilars among Ukrainian physicians.